MRK
MRK
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
MRK
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest MRK headlines
- Merck Q3 results show oncology launches and pipeline advances alongside margin headwinds [1]. - MRK stock rallied as Q3 earnings eased profit pressure [3]. - Merck shares rose on Friday [4].
Generated Nov 01, 2026 · 10:59 UTC
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds — Yahoo Finance
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data — Yahoo Finance
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze — Yahoo Finance
- Why Merck Stock Flew Higher on Friday — Yahoo Finance
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Some history or news is missing or stale. Available cached data remains visible; background requests respect provider retry backoff. Reload this range to check again.
Historical price
251 observations · USD · Source: Yahoo Finance · Oct 31, 2025 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about MRK
- MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds ↗
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine Data ↗
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze ↗
- Why Merck Stock Flew Higher on Friday ↗
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs ↗
- CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting Ceremony ↗
- This week in charts: ESMO’s winners and losers ↗
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales ↗
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends ↗
- Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex Diagnostics ↗
- AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth ↗
- Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook ↗
- Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe? ↗
- Is 50% Crash Risk For Iovance Stock Real? ↗
- Merck & Co., Inc. Q3 Earnings Call Highlights ↗
- What Sent Eli Lilly Stock Higher? ↗
- Has The Story Under Johnson & Johnson Stock Run Out? ↗
- Company News for Oct 30, 2026 ↗
- Merck & Co., Inc. Q3 2026 Earnings Call Summary ↗
- Merck (MRK) Turns Heads With Phase 3 Endometrial Cancer Data And FDA Review ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.